Simulations Plus/$SLP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Simulations Plus
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Ticker
$SLP
Sector
Primary listing
Industry
Health Care Technology
Headquarters
Employees
245
ISIN
US8292141053
Website
Simulations Plus Metrics
BasicAdvanced
$344M
47.54
$0.36
1.10
$0.06
1.40%
Price and volume
Market cap
$344M
Beta
1.1
52-week high
$49.71
52-week low
$16.72
Average daily volume
438K
Dividend rate
$0.06
Financial strength
Current ratio
4.368
Quick ratio
3.542
Long term debt to equity
0.255
Total debt to equity
0.42
Dividend payout ratio (TTM)
33.09%
Profitability
EBITDA (TTM)
11.266
Gross margin (TTM)
55.28%
Net profit margin (TTM)
9.24%
Operating margin (TTM)
7.85%
Effective tax rate (TTM)
14.90%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
1.98%
Return on equity (TTM)
3.96%
Valuation
Price to earnings (TTM)
47.541
Price to revenue (TTM)
4.369
Price to book
1.82
Price to tangible book (TTM)
9.33
Price to free cash flow (TTM)
41.759
Free cash flow yield (TTM)
2.39%
Free cash flow per share (TTM)
41.00%
Dividend yield (TTM)
0.35%
Forward dividend yield
1.40%
Growth
Revenue change (TTM)
21.49%
Earnings per share change (TTM)
-30.71%
3-year revenue growth (CAGR)
16.39%
10-year revenue growth (CAGR)
18.49%
3-year earnings per share growth (CAGR)
-13.69%
10-year earnings per share growth (CAGR)
7.18%
3-year dividend per share growth (CAGR)
-20.63%
10-year dividend per share growth (CAGR)
-3.42%
What the Analysts think about Simulations Plus
Analyst ratings (Buy, Hold, Sell) for Simulations Plus stock.
Bulls say / Bears say
Simulations Plus reported a 33% year-over-year increase in fourth-quarter revenue to $15.6 million, driven by a 59% surge in software revenue, indicating strong demand for its products. (businesswire.com)
The company's acquisition of Immunetrics has expanded its capabilities in quantitative systems pharmacology, potentially opening new revenue streams in immunology and oncology markets. (businesswire.com)
Simulations Plus maintains a strong gross margin of 78% in the fourth quarter, reflecting effective cost management and a favorable product mix. (businesswire.com)
BTIG reduced its price target for Simulations Plus from $60 to $50, citing revenue and adjusted EBITDA figures that fell short of expectations. (investing.com)
The company's net income decreased to $0.5 million in the fourth quarter, down from $1.0 million in the same period the previous year, indicating potential profitability challenges. (businesswire.com)
Simulations Plus discontinued its quarterly dividend to reallocate funds towards growth initiatives, which may concern income-focused investors. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Simulations Plus Financial Performance
Revenues and expenses
Simulations Plus Earnings Performance
Company profitability
Simulations Plus News
AllArticlesVideos
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
Business Wire·1 week ago
52-Week Lows? No Problem for 3 Stocks With Big Upside Potential
MarketBeat·1 week ago
Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Simulations Plus stock?
Simulations Plus (SLP) has a market cap of $344M as of June 27, 2025.
What is the P/E ratio for Simulations Plus stock?
The price to earnings (P/E) ratio for Simulations Plus (SLP) stock is 47.54 as of June 27, 2025.
Does Simulations Plus stock pay dividends?
Yes, the Simulations Plus (SLP) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $0.06 and the yield is 1.4%. Simulations Plus has a payout ratio of 33.09% on a trailing twelve-month basis.
When is the next Simulations Plus dividend payment date?
The next Simulations Plus (SLP) dividend payment date is unconfirmed.
What is the beta indicator for Simulations Plus?
Simulations Plus (SLP) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.